Neurocrine: 2Q Earnings Snapshot

July 31, 2018

SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Tuesday reported a loss of $5.9 million in its second quarter.

On a per-share basis, the San Diego-based company said it had a loss of 7 cents.

The results surpassed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share.

The biopharmaceutical company posted revenue of $96.9 million in the period, which also topped Street forecasts. Six analysts surveyed by Zacks expected $84.5 million.

Neurocrine shares have increased 30 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $100.49, more than doubling in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NBIX at https://www.zacks.com/ap/NBIX

Update hourly